Table 4. Association of clinical and pathological pre and post-NAC parameters with overall survival after univariate and multivariate analysis in the whole population.
| Univariate | Multivariate | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Class | Number | Events | HR | CI | p* | p | HR | CI | p |
| Pre-NAC parameters | ||||||||||
| Age (years) | <45 | 285 | 57 | 1 | 0.514 | |||||
| 45–55 | 254 | 48 | 0.96 | [0.65–1.41] | ||||||
| >55 | 178 | 28 | 0.77 | [0.49–1.21] | ||||||
| Menopausal status | pre | 451 | 80 | 1 | 0.457 | |||||
| post | 259 | 51 | 1.14 | [0.8–1.62] | ||||||
| BMI | 19≤BMI≤25 | 414 | 74 | 1 | 0.837 | |||||
| <19 | 41 | 8 | 1.14 | [0.55–2.36] | ||||||
| >25 | 261 | 51 | 1.1 | [0.77–1.58] | ||||||
| Tumor size | T1 | 47 | 8 | 1 | 0.007 | 1 | - | - | ||
| T2 | 481 | 78 | 0.92 | [0.44–1.91] | 0.823 | 0.74 | [0.35–1.55] | 0.422 | ||
| T3 | 189 | 47 | 1.64 | [0.77–3.47] | 0.197 | 1.23 | [0.57–2.66] | 0.594 | ||
| Clinical nodal status | N0 | 282 | 48 | 1 | 0.463 | |||||
| N1-N2-N3 | 434 | 85 | 1.14 | [0.8–1.63] | ||||||
| Mitotic index | ≤22 | 389 | 64 | 1 | 0.014 | |||||
| >22 | 293 | 66 | 1.54 | [1.09–2.18] | 0.014 | |||||
| Histology | ductal | 660 | 121 | 1 | 0.65 | |||||
| other | 53 | 11 | 1.15 | [0.62–2.14] | ||||||
| Grade | I-II | 211 | 36 | 1 | 0.291 | |||||
| III | 490 | 94 | 1.23 | [0.84–1.81] | ||||||
| Ki67 | <20 | 33 | 5 | 1 | 0.33 | |||||
| ≥20 | 146 | 35 | 1.59 | [0.62–4.07] | ||||||
| Subtype | luminal | 224 | 19 | 1 | <0.001 | 1 | - | - | ||
| TNBC | 311 | 59 | 2.77 | [1.65–4.65] | 0.075 | 2.7 | [1.8–4.05] | <0.001 | ||
| HER2 | 181 | 3 | 0.24 | [0.07–0.83] | <0.001 | 0.51 | [0.24–1.08] | 0.078 | ||
| ER status | negative | 396 | 80 | 1 | 0.049 | |||||
| positive | 321 | 53 | 0.71 | [0.5–1] | 0.049 | |||||
| PR status | negative | 473 | 93 | 1 | 0.052 | |||||
| positive | 221 | 33 | 0.67 | [0.45–1] | 0.052 | |||||
| HER2 status | negative | 541 | 122 | 1 | <0.001 | |||||
| positive | 176 | 11 | 0.25 | [0.13–0.46] | <0.001 | |||||
| NAC regimen | AC | 61 | 13 | 1 | 0.489 | |||||
| AC-Taxanes | 576 | 110 | 0.96 | [0.54–1.72] | ||||||
| Others | 80 | 10 | 0.65 | [0.29–1.49] | ||||||
| TILs | (continuous) | 0,99 | [0.98–0.99] | 0,01 | ||||||
| Post-NAC parameters | ||||||||||
| Nodal involvment | 0 | 445 | 51 | 1 | <0.001 | |||||
| 1–3 | 188 | 46 | 2.1 | [1.41–3.13] | <0.001 | |||||
| ≥4 | 84 | 36 | 4.24 | [2.76–6.5] | <0.001 | |||||
| RCB class | pCR | 202 | 12 | 1 | <0.001 | 1 | - | - | ||
| RCB-I | 65 | 2 | 0.55 | [0.12–2.45] | 0.43 | 0.75 | [0.17–3.38] | 0.711 | ||
| RCB-II | 309 | 68 | 3.85 | [2.09–7.12] | <0.001 | 4.17 | [2.21–7.86] | <0.001 | ||
| others | 141 | 51 | 6.59 | [3.51–12.37] | <0.001 | 6.6 | [3.28–13.27] | <0.001 | ||
| LVI | no | 500 | 66 | 1 | <0.001 | 1 | - | - | ||
| yes | 148 | 55 | 3.07 | [2.15–4.39] | <0.001 | 1.76 | [1.21–2.57] | 0.003 | ||
| TILs | (continuous) | 0,99 | [0.99–1.02] | 0,329 | ||||||
Abbreviations: pCR = pathological complete response; BMI = body mass index; NST = no special type; ER = oestrogen receptor; PR = progesterone receptor; NAC = neoadjuvant chemotherapy; AC = anthracyclines; TILs = tumor infiltrating lymphocytes; RCB = residual cancer burden; LVI = lymphovascular invasion.